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The initiation, progression, and metastasis of tumors involve not only cancer cells, but 
also the tumor microenvironment, which consists of immune or inflammatory cells, 
fibroblasts, endothelial cells, and extracellular matrix components (ECM). Fibroblasts are 
ubiquitous stromal cells that can influence other neighboring cell types through the 
secretion of chemokines, cytokines, ECM, ECM remodeling enzymes, and other 
metabolites. Myofibroblasts are a distinct subtype of fibroblasts characterized by 
expression α-smooth muscle actin (αSMA). These cells are a dominant component of the 
microenvironment, and a FSP1 and FAP could be a different clone of fibroblasts. 
Myofibroblasts also have been known to contribute to cancer progression and metastasis 
in multiple cancer types including breast and pancreas cancer, both of which are 
associated with extensive desmoplasia. However, the role of αSMA+ myofibroblasts in 
the context of colorectal cancer has remained largely descriptive and functionally 
unknown. The studies outlined in this project explored the functional contribution of 
αSMA+ myofibroblasts in the disease progression of colorectal cancer. To address this, 
we used the spontaneous colorectal cancer model, which consists of 6 alleles: Villin-Cre-
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ERT2; APCflox/flox; p53flox/flox; tetO-LSL-KrasG12D; Rosa26-LSL-Luc; Rosa26-LSL-rtTA-
eGFP. These mice were bred with αSMA-TK and αSMA-RFP transgenic mice for 
selective targeting and monitoring of myofibroblasts in the tumor microenvironment in 
these eight allelic transgenic mice.  
Mice with αSMA+ myofibroblast-depleted tumors exhibited hind limb paresis, which 
likely contributed to their decreased overall survival. Intraluminal tumor burden appeared 
reduced in myofibroblast-depleted tumors; however, the tumors were depressed resulting 
in more invasion to both the vascular and lymphatic vessels. The depletion of 
myofibroblast surprising resulted in increased deposition of ECM and generation of an 
immunosuppressive microenvironment with the accumulation of CD4+ Foxp3+ Treg. 
Furthermore, we discovered that the population of cancer stem cells expressing Lgr5 and 
Dclk1 was increased in αSMA+ myofibroblast-depleted tumors. In conclusion, our study 
reveals the unknown functional role of myofibroblasts in regulating T cell-meditated anti-
tumor immunity and stemness features in colon cancer cells. 
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Chapter 1: Introduction 
Epidemiology of colorectal cancers  
Colorectal cancers (CRCs) are a frequently lethal disease with heterogeneous outcomes 
and drug responses. Incidence is low at ages younger than 50 years but strongly increases 
with ages. Median age at diagnosis is around 70 years in developed countries [1]. The 
highest incidence has been reported in countries of Europe, North America, whereas 
incidence is lowest in some countries of south and central Asia and Africa [2]. In the 
United States, CRC is the second or third leading cause of cancer and cancer-related 
deaths, with a 2016 estimate 134,490 new cases diagnosed and 49,190 death. The lifetime 
risk of developing CRC is as high as 5% in the American population.  
The prognosis of patients with CRC has slowly but steadily improved during past 
decades in many Western countries. Overall survival decreases with age and relative 
survival at the young age is slightly higher for women than for men. The Stage at 
diagnosis is the most critical prognostic factor. In the United States in 2001 - 2007, 5-
year survival rate for CRC patients with a local stage was 90.1%, 69.2% for patients with 
regional spread, and 11.7% for patients with distant spread [1].   
Epidemiological studies have identified that no single risk factor accounts for most cases 
of CRC. The following risk factors such as family history of CRC [3], inflammatory 
bowel disease [4], smoking [5], excessive alcohol consumption [6], high consumption of 
red and processed meat [7], obesity [8], and diabetes [9] co-occur and interact for 
development of CRC. Further recent evidence suggested that infection of Helicobacter 
pylori and Fusobacterium spp. could be associated with an increased risk of CRC 
incidence [10, 11]. Established preventive factors contain physical activity [12], 
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treatment of hormone replacement therapy [13] and aspirin [14, 15], and removal of 
precancerous lesions via endoscopic procedure showing most promising risk reduction 
[16, 17].   
 
Histopathological classification of colorectal cancers  
CRCs are histopathologically classified according to local invasion depth (T stage), 
lymph node dissemination (N stage), and the presence of distal metastasis (M stage) 
(Table 1) [131].  These classifications are combined into overall stage definition to 
provide the decision for therapeutic treatments (Table 2). Although this classification 
according to TNM stage provides valuable prognostic information and guide therapeutic 
decisions, the outcome of CRC patients’ treatment is difficult to predict.  
 
Diagnosis and staging of colorectal cancers  
A general diagnosis of CRCs depends on biopsy samples taken during endoscopy. 
Complete endoscopy or computed tomography (CT) endoscopy is necessary to detect 
synchronous cancers that are present in about 2 - 4 % of CRC patients [18]. For rectal 
cancer, exact local staging at the time of diagnosis is critical for neoadjuvant treatment. 
Endoscopic ultrasonography is the accurate method for determination of regional T stage 
of rectal cancer because of its accuracy to determine between non-invasive and invasive 
phenotype [19]. Magnetic Resonance Imaging (MRI) is the most accurate method to 
define advanced T stage of rectal cancer [20].  
The most common location of metastasis in CRC patients is the liver, and a meta-analysis 
with patients without any treatments display that the sensitivity of MRI is slightly higher 
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than that of CT [21] Especially, MRI had significantly higher sensitivity than CT for 
small tumors less than 10 mm. Abdominal ultrasonography is the common diagnostic 
method for detection of many cancers in the abdomen, but its sensitivity to detect liver 
metastasis was lower than any other staging methods [22].  To identify lung metastasis, 
the chest radiograph is utilized, and chest CT considers as another option for patients 
with locally advanced rectal cancers [23].  
 
Standard cares of colorectal cancers  
The surgery is the main treatment for early-stage CRCs. The standard surgical procedure 
for early treatment of rectal caner patients is excision of total mesorectum [24]. Complete 
removal of the mesorectum is critical because it contains most of the tumor deposits and 
involved lymph nodes [25]. For colon cancer patients, the tumors and the surrounding 
lymphatic vessels are surgically removed. Unlike open surgery, laparoscopic resection 
provides the patients with reduced blood transfusions, faster return of bowel function, and 
a shorter duration of hospital stay. However, operating times are longer, and operative 
costs are higher than open surgery.  
The role of neoadjuvant therapies including radiotherapy and chemotherapy is not only to 
downsizing or staging of tumors but also to reduce local recurrence rates after surgery. 
Patients with stage I CRCs are not necessary for any treatments before surgery because 
local recurrence rate is less than 3% [26]. These clinical treatments are known to provide 
benefits for patients with T4 and advanced T3 tumors infiltrating mesorectal fascia.  
Patients with stage III CRCs have a high risk of recurrence rating between 15% and 50%. 
Adjuvant chemotherapy, therefore, is highly recommended for all patients with stage III 
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CRCs after curative resection. Fluorouracil treatment reduced the recurrence rate by 17% 
and increased five-year disease free survival (DFS) by 13-15% [27]. Alternatively, 
Capecitabine, an oral prodrug of fluorouracil has been used for comparable efficacy [28].  
Additionally, oxaliplatin increased the 5-year disease-free survival rate by 6.2% to 7.5% 
and overall survival by 2.7% to 4.2% in patients with stage III CRCs [29, 30].  
 
Molecular pathogenesis of colorectal cancers  
The patterns of the molecular pathogenesis of CRCs are highly heterogeneous. The 
molecular mechanisms underlying development and progression of CRCs are clinically 
important because they are tightly associated with the prognosis and therapeutic 
approaches of patients [31, 32]. During past two decades, therefore, the identification of 
molecular mechanisms including genetic alterations has been focused on improving 
responses to treatments.   
One of the most critical fundamental concepts of colorectal tumorigenesis is adenoma-
carcinoma sequence, a term that describes the stepwise progression from normal 
epithelium to dysplastic lesion called adenoma to carcinoma associated with the 
accumulation of multiple genetic alterations [33].  The concept was first proposed by 
Fearon and Vogelstein in 1990 and postulated that mutational activation of oncogenes, 
coupled with mutational inactivation of tumor suppressor genes leads to the development 
of colorectal cancer. They tested their hypothesis by measuring the frequency of ras gene 
mutation and loss of p53 in early adenoma, intermediated adenoma, late adenoma, and 
carcinoma. Approximately 50% of colorectal carcinomas and the similar percentage of 
intermediated adenoma and late adenoma have been found ras mutation. However only 
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10% of early adenomas have exhibited ras mutation. The loss of a large portion of p53 
has been seen in more than 75% of carcinoma, but such loss is infrequent in any stages of 
adenomas [34].  
CRCs often develop over more than 10 years and dysplastic adenomas are the most 
common form of premalignant precursor lesions [35]. One of the mutations known to 
occur early in the adenoma-carcinoma progression is the adenomatous polyposis coli 
(APC) tumor suppressor gene located on chromosome 5q21 in human [132] [36]  and, 
this mutation occurs in more than 70% of adenomas [37]. The protein of APC gene is a 
large 312-kDa protein composed 2843 amino acids. It is known as a multifunctional 
protein with several domains that interact with several proteins including the β-catenin, 
glycogen synthase kinase (GSK) 3β, and end binding protein (EB) 1 [38-40].  One critical 
function of APC to colorectal tumorigenesis is the regulation of intracellular β-catenin 
levels. Wild-type APC protein forms a complex with β-catenin and GSK-3β, which leads 
to an enhanced rate of β-catenin degradation by the ubiquitin-proteasome pathway. C-
terminally truncated mutant APC proteins, however, lack of β-catenin binding site, cause 
to increase intracellular β-catenin level [133] [41]. The importance of β-catenin relates to 
its capacity to bind T-cell factor (TCF) family of transcriptional factors and activate gene 
transcriptions [42]. Increased β-catenin-TCF-meditated transcription has been 
demonstrated in tumors with APC mutations and β-catenin mutation and results in 
increased transcriptional activity of target genes such as oncogenic c-myc [134].  
An additional genetic alteration presumably occurs early in the adenoma-carcinoma 
progression is the mutation in the K-ras gene. K-ras is one of three members of Ras 
family located on the short arm of chromosome 12 and associated with somatic mutations 
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in many human cancers. The type of K-ras somatic mutations found in around 40% of 
CRCs is point mutations affecting codon 12, 13, or 61. Especially, more than 75% of the 
K-ras point mutations occur at the codon 12. Only small fraction (< 5%) of CRCs has N-
ras mutations at codon 12, 13, or 61 [34]. K-ras encodes 21-kDa protein critically 
involved in signal transduction of regulatory pathways for proliferation and 
differentiation [43].  It is guanosine 5'-triphosphate (GTP)-binding protein, located at the 
cytoplasmic aspect of the cell membrane. When bound to GTP, the ras protein is active 
but becomes inactive when GTP is hydrolysed to guanosine 5’-diphosphate. Mutations of 
the K-ras oncogene impact the GTP-binding domain, decrease its GTPase activity and 
result in a constitutively active Ras protein [137].  
The p53 gene is the most frequently mutated in human cancers, which located on short 
arm of chromosome 17 [44]. The functional role of p53 is to block cell proliferation in 
the presence of DNA damage, to stimulate DNA repair, and promote apoptotic cell death 
if repair is not sufficient [45].  Loss of p53 function, therefore, results in propagation of 
damaged DNA to daughter cells. Functional inactivation of p53 most often occurs as a 
result of missense mutations in the DNA-binding domain, but it can result from 
oncogenic viral or cellular protein interaction [46, 47]. The alteration of p53 has been 
reported in 4-26 percent of adenomas, in approximately 50 percent of invasive foci within 
adenomatous polyps, and in 50-75 percent of adenocarcinomas [48], [135-136]. These 
results lead to the belief that functional inactivation of p53 protein is associated with the 
transition from adenoma to carcinoma. 
However, more than 15% of sporadic CRCs develop through fundamentally different 
molecular events instead of generic adenoma-carcinoma sequence. These subtypes of 
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tumors are originated from serrated precursor lesions and often characterized by the CpG 
island methylation and activating oncogenic BRAF mutations. It is difficult to identify 
these lesions during colonoscopy because these cancers are relatively flat and 
inconspicuous characteristics [49]. Most cancers arising from serrated adenomas show 
the high-level microsatellite instability (MSI-H) phenotype as a result of promoter 
methylation of MLH1 gene [50], and appear in the proximal colon of elderly women [51].  
Hereditary CRCs contribute to around 3-5% of all CRC cases [52, 53]. Dissecting 
mechanisms related to hereditary forms is valuable to study molecular pathogenesis of 
CRCs. Hereditary CRCs display inactivated tumor suppressor genes or DNA repair genes 
by a germ line mutation and a somatic event abrogating the remaining wild-type allele 
leading to tumor formation [54]. The two most common forms of hereditary CRCs are 
hereditary non-polyposis colon cancer (Lynch syndrome) and familial adenomatous 
polyposis coli (FAP). Both syndromes are autosomal dominant disorders. Whereas Lynch 
syndrome indicates mismatch repair deficiency and MSI-H [52, 55], FAP syndrome 
follows the classic adenoma-carcinoma sequence [56].  
Mismatch repair deficient CRCs are defined by the accumulation of insertion and 
deletion mutations at microsatellites spread along the genome [55]. Clinical 
characteristics of MSI-H cancers exhibit development of tumors in the proximal colon, 
the symptom in people younger than 50 years (hereditary form) or elderly people 
(sporadic form), simultaneous occurrence of additional cancers [57], and relatively large 
primary tumors with rare distal metastasis. Histopathologically, MSI-H cancers display 
poor or mixed differentiation with dense infiltration with tumor infiltrating lymphocytes 
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and expansive pattern of invasion [58]. MSI-H cancers also exhibit loss of expression of 
at least one DNA mismatch repair protein in greater than 90% of lesions [59].  
 
Tumor microenvironment (TME) 
In CRCs, the multistep process from normal colonic epithelium to an adenomatous polyp 
and ultimately to an invasive adenocarcinoma is associated with a robust desmoplastic 
reaction, which generates complex tumor microenvironment. Desmoplasia is activation 
of stoma cells by cancer cells not only to eliminate the pre-existing extracellular matrix 
but also to induce new matrix formation [60].  The tumor microenvironment consists of 
cells of hematopoietic origin, cells of mesenchymal origin, active angiogenesis, 
extracellular matrix (ECM), and proteins and remodeling enzymes [61, 62].  
Local inflammation at the site of solid tumors causes the accumulation of a variety of 
cells, and it is now widely accepted that these cells are intimately linked to the control of 
tumor growth. CRC, similarly to many other solid tumors, are infiltrated by immune cells 
such as tumor-associated macrophages (TAMs), myeloid-derived suppressor cells 
(MDSCs), monocytes, neutrophils, T cells, B cells, NK cells, and dendritic cells (DCs) 
and stroma cells such as endothelial cells, endothelial progenitor cells (EPCs), pericytes, 
platelets, mesenchymal stem cells (MSCs), and cancer-associated fibroblasts (CAFs).  
TAMs are typically derived from blood monocytes that are recruited to the tumors by 
growth factors and chemokines such as vascular endothelial growth factor (VEGF), 
colony-stimulating factor-1 (CSF-1), CCL2, CCL3, CCL4, CCL5, and angiopoietin-2 
[63]. Recruited monocytes differentiate into TAM upon the presence of low interleukin 
(IL)-12 and high IL-10 concentration in TME [64]. It has been well established that 
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macrophage-deriving tumor necrosis factor (TNF) – α, IL-1β, and IL-6 induce human 
colon cancer cell proliferation and migration, and also colon cancer cells stimulate 
macrophages to produce IL-6 via signal transducer and activator of transcription 3 
(STAT3) – mediated IL-10 production [65, 66]. (explaining in detail) Clinically, elevated 
IL-10 and IL-6 are associated with a poor prognosis in CRC patients [67].   
MDSCs are immature myeloid cells that have the immunosuppressive affect. The 
suppressive effects of MDSCs are associated with metabolism of L-arginine that is the 
substrate for arginase-1 and inducible nitric oxide synthase (iNOS). Arginase-1 degrades 
arginine in TME, which affect translational blockade of ε chain of CD3 leading to 
prevention of T cell stimulation from tumor antigens. iNOS-mediated nitric oxide (NO) 
production inhibits T cell function via a variety of different mechanisms including the 
blockade of phosphorylation and activation of Janus kinase 3 and STAT5, inhibition of 
MHC-II gene expression, and induction of T cell apoptosis [68]. Also, there is emerging 
evidence that MDSCs promote the development of Foxp3+ Tregs by releasing IL-10 and 
TGF-β [69]. It is widely known that the number of MDSCs is increased in the blood of 
patients with solid cancers including CRCs [70]. 
CD4+ CD25+ Foxp3+ Tregs are also expanded in TME and are capable of suppressing the 
proliferation of cytotoxic and effector T cells through direct contact or IL-10 and TGF-β 
production. IL-17-producing CD4+ CD25+ Foxp3+ Tregs expanded in colonic polyps 
promotes mastocytosis and tumor-promoting inflammation [71]. Also, CD4+ CD25+ 
Foxp3+ Tregs express cyclooxygenase-2 (COX-2) which are overexpressed in the 
majority of CRCs [72] and COX-2-derived prostaglandin E2 (PGE2) promote tumor 
growth by inducing cell proliferation, survival, and invasion [73]. Treatment of long-term 
	 10	
nonsteroidal anti-inflammatory drugs (NSAIDs) increased the levels of MHC II proteins 
such as HLA-DP, HLA-DQ, and HLA-DR, and infiltration of CD4+ effector T cells and 
CD8+ cytotoxic T cells in TME along with decreased Treg-associated molecules 
including IL-10 and Foxp3 [74, 75].  
 
Fibroblasts 
Fibroblasts are dominant population of tumor stroma, and many studies suggested that 
these cells support cancer progression and metastasis [76, 77]. Fibroblasts in TME have 
been termed cancer-associated fibroblasts (CAFs), tumor-associated fibroblasts (TAFs), 
activated fibroblasts or myofibroblasts. CAFs are considered as a major contributor of 
fibrotic stroma in many solid tumors [78, 79]. 
Fibroblasts are non-epithelial cells and non-immune cells with the mesenchymal origin 
and a part of connective tissues [138]. Fibroblasts in healthy tissue are quiescent with 
negligible metabolic activity. The fibroblasts are usually resting state and become 
activated in a wound healing response [80]. These activated fibroblasts were termed as 
myofibroblasts. Myofibroblasts are regarded as involving acute and chronic inflammation 
and tissue fibrosis [81, 82].  
Fibroblasts in mammals are highly heterogeneous, and fibroblasts isolated from different 
organs reflect tremendous topographic diversity. A recent study by using the genome-
wide expression patterns of human fibroblast culture isolated from 16 various sites 
indicated that the gene expression pattern of human fibroblast lineage is comparable with 
that of human white blood cells [83]. There are several well-established fibroblast 
markers including vimentin, alpha-smooth muscle actin (αSMA), Desmin, Fibroblast-
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specific protein1 (FSP-1), and Fibroblast-activation protein (FAP), but none of them are 
commonly expressed fibroblast lineage [84]. 
Myofibroblasts are spindle shape of contractile cells functioning as remodeling of 
damaged tissues. The transition from fibroblast to myofibroblasts during wound healing 
is a stepwise process in which fibroblast first differentiate into proto myofibroblasts by 
expressing β-cytoplasmic actin and γ-cytoplasmic actin and then fully differentiate into 
myofibroblasts which express αSMA [85].  
αSMA is currently considered the most common marker of intestinal myofibroblasts that 
also expressed on pericytes, bone marrow-derived mesenchymal stromal cells, muscularis 
mucosae smooth muscle cells, and mural cell associated with lymphatic lacteals. αSMA 
expressing cells in the core of villi are mostly pericytes where αSMA expressing cells 
located in under epithelial layer around crypts of small and large intestines are 
myofibroblasts [86].  
Fibroblasts play a critical role in all stages of cancer progression including tumor 
initiation, growth, invasion, and metastasis. Mostly this involvement of fibroblasts in 
cancer is typically based on their specific functions in each stage of cancer. In the 1970s, 
several studies led to the consideration that cancer cells may recruit activated fibroblasts 
[139] [87, 88]. This recruitment of fibroblasts is regulated by the growth factors released 
by cancer cells and other immune cells. The recruitment of activated fibroblasts is mainly 
associated with transforming growth factor-β (TGF- β) and also the proliferation of CAFs 
is regulated by TGF- β [89, 90]. The role of CAFs in TME may involve the crosstalk with 
cancer cell to promote tumor growth and stemness, immunosurveillance, activation of 
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angiogenesis, tumor-promoting inflammation, and ECM remodeling that facilitate 
metastasis. 
 
Cancer stem cells  
The intestine is one of most rapidly renewing tissues in the human body in that the entire 
epithelial layer is replaced within every 5 days. This rapid process is maintained by 
intestinal stem cells (ISCs) that localize in the bottom of the crypt and generate precursor 
cells. These precursor cells differentiate into specialized cells, mainly enterocytes that 
uptake nutrients as well as transport and remove faeces that is facilitated by mucin-
producing goblet cells [91]. Another abundant differentiated cells are hormone-producing 
enteroendocrine cells and Paneth cells. Paneth cells reside at the bottom of crypt, function 
in intestinal immunity, and contribute to the formation of the ISCs niche [92].  
Due to its high turnover rate, the intestinal epithelium is subject to malignant 
transformation like CRCs. Interestingly, the biology of ISCs and CRCs is highly 
interconnected. Signaling pathways that regulate ISC function such as WNT signaling are 
aberrantly activated in CRC patients [34]. Most of the intestinal cancers originate from 
initial transforming events in the ISC compartment. Cancer cells that share properties of 
ISCs, including multilineage potential and self-renewal, appeared in CRCs and are 
referred to colon cancer stem cells (CSCs) [93]. These CSCs are thought to contribute to 
tumor growth and progression, but there are still many unknown properties regarding 
their identification and importance for clinical implication. 
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    Definition 
   
 
T stage 
 
 
Tx No information about local tumour infiltration available 
 
Tis Tumour restricted to mucosa, no infiltration of lamina muscularis mucosae 
 
T1 Infiltration through lamina muscularis mucosae into submucosa,  
  
no infiltration of lamina muscularis propria 
 
T2 Infiltration into, but not beyond, lamina muscularis propria 
 
T3 Infiltration into subserosa or non-peritonealised pericolic or perirectal tissue,  
  
or both; no infiltration of serosa or neighboring organs 
 
T4a Infiltration of the serosa 
 
T4b Infiltration of neighboring tissues or organs 
   
 
N stage 
 
 
Nx No information about lymph node involvement available 
 
N0 No lymph node involvement 
 
N1a Cancer cells detectable in 1 regional lymph node 
 
N1b Cancer cells detectable in 2–3 regional lymph nodes 
 
N2a Tumour satellites in subserosa or pericolicor perirectal fat tissue,  
  
 regional lymph nodes not involved 
 
N2b Cancer cells detectable in 4–6 regional lymph nodes 
 
N2b Cancer cells detectable in 7 or greater regional lymph nodes 
   
 
M Stage 
 
 
Mx No information about distant metastases available 
 
M0 No distant metastases detectable 
 
M1a Metastasis to 1 distant organ or distant lymph nodes 
 
M1b Metastasis to more than 1 distant organ or set of distant lymph nodes 
  
or peritoneal metastasis 
      
 
Table 1. Classification of CRC according to local invasion depth (T stage), lymph node 
involvement (N stage), and presence of distant metastases (M stage) 
Adapted by Fl. Obrocea et al, (2011) [131] 
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    T stage N stage M stage 
     
 
Stage 0 Tis N0 M0 
 
Stage I T1/T2 N0 M0 
 
Stage II T3/T4 N0 M0 
 
IIA T3 N0 M0 
 
IIB T4a N0 M0 
 
IIC T4b N0 M0 
 
Stage III Any N+ M0 
 
IIIA T1-T2 N1 M0 
  
T1 N2a M0 
 
IIIB T3-T4a N1 M0 
  
T2-T3 N2a M0 
  
T1-T2 N2b M0 
 
IIIC T4a N2a M0 
  
T3-T4a N2b M0 
  
T4b N1-N2 M0 
 
Stage IV Any Any M+ 
 
IVA Any Any M1a 
 
IVB Any Any M1b 
          
 
Table 2. Overall stage classification of CRCs 
Adapted by Fl. Obrocea et al, (2011) [131]  
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Chapter 2: Material and methods 
Mice 
Mouse colorectal cancer model containing six genetic alleles; VillinCreERT2; tetO-Lox-
Stop-Lox-KrasG12D; ROSA26-Lox-Stop-Lox-rtTA-IRES-EGFP; APCfl/fl; P53fl/fl; ROSA26-
Lox-Stop-Lox-Luciferase (herein referred to as iKrAP) mice were kindly provided by Dr. 
Adam T. Boutin in the laboratory of Dr. Ronald A. DePinho at MD Anderson Cancer 
Center (MDACC). Tamoxifen-dependent Cre recombinase (VillinCreERT2) was expressed 
under the control of a 9 kb regulatory region of villin gene and led to spatiotemporally 
controlled somatic recombination for targeted genes after tamoxifen administration. tetO-
Lox-Stop-Lox-KrasG12D transgene was controlled by tetracycline-response operon 
promoter element (tetO) with a lox-stop-lox cassette inserted between the promoter and 
the start codon of the KrasG12D open reading frame. The Cre recombinase-mediated 
excision of a STOP codon in ROSA26-Lox-Stop-Lox-rtTA-IRES-EGFP transgene-
induced functional reverse tetracycline transactivator (rtTA) and EGFP activity, which 
were inserted between exon 1 and exon 2 in the ROSA26 locus. In the presence of 
doxycycline, rtTA bound to tetO and initiated transcription of KrasG12D. Conditional APC 
knockout was regulated by Cre-loxP strategy leading to deletion of exon 14 and 
generation of a frameshift mutation at AA580 that disrupted that APC gene.                    
iKrAP mice were first bred with αSMA-TK mice and then bred with αSMA-RFP mice. 
All mice were housed under standard housing conditions at MDACC animal facilities, 
and all animal procedures were reviewed and approved by the MDACC Institutional 
Animal Care and Use Committee.  
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Tumor induction  
4-OH tamoxifen (Sigma-Aldrich, H7904) was solubilized in 100% ethanol (50 mg/ml) 
and diluted to 1 mg/ml in 100% ethanol. iKrAP; αSMA-TK; αSMA-RFP mouse (8-10 
weeks of ages) of known weight was lightly anesthetized by placing in a plastic chamber 
containing isoflurane. A 20 gauge and 30 mm plastic feeding tube (Instech, FTP203050) 
attached to 1 ml disposal syringe was filled with 1mg/ml of 4-OH tamoxifen mixture, and 
the tube was lubricated by dipping the soft elastomer tip in surgical lubricant. The 
anesthetized mouse was held by the tail. A plastic feeding tube was inserted into the anus 
around 2 to 2.5 cm and 50 ul of 1 mg/ml of 4-OH tamoxifen mixture was injected into its 
rectum. The mouse was held by the tail in a vertical position, head down, for 30 sec to 
allow uniform distribution of the 4-OH tamoxifen mixture before putting the mouse back 
in its cage. The moue was fed with Doxycycline pellets (200 mg/kg, BioServ, S3888) 
instead of normal chow after intrarectal administration of 4-OH tamoxifen mixture.  
 
Endoscopic procedures 
For monitoring the tumorigenesis, Storz Veterinary video endoscopic system was utilized 
(Karl Storz, Germany). The endoscopic system consisted of a miniature endoscope 
(scope 1.9 mm outer membrane) including a telescope and a telescope sheath, a light 
source, a camera console, USB recorder, a monitor, and an endoflator to regulate inflated 
mouse colon. The endoscopic procedure was viewed on a color monitor and digitally 
recorded on USB flash drive. Before anesthetizing the mouse, an endoscope and a camera 
console were assembled and were sterilized by dipping the tip in 10% bleach and 70% 
ethanol to prevent disease transmission. The mouse was anesthetized by placing in a 
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plastic chamber containing isoflurane until completely anesthetized. A 20 ga x 30 mm 
plastic feeding tube attached to 10 ml disposal syringe was filled with a warm PBS. The 
tube was coated with the sterile surgical lubricant and inserted into the anus to flush the 
colon with a warm PBS enema (10ml). The anesthetized mouse was placed on the 
operation table applied with the nose cone that provided the inhalation anesthesia to the 
mouse. The lubricated endoscope was inserted into the anus and advanced through the 
rectum. The air from an endoflator was slowly applied to set apart the intestinal walls. 
The rectum and colon were carefully assessed and monitored, and the video was recorded 
if tumors and colonic inflammation were identified. Upon the completion of examination, 
the endoscope was slowly withdrawn, and the mouse was provided with a warm 
environment in which its cage was placed on a warm pad. The mouse was monitored 
closely until full recovery.    
 
GCV treatment 
Ganciclovir (GCV) was utilized to obtain a suicide effect in αSMA-TK+ cells. GCV is an 
analog of deoxyguanosine used as a substrate, which is converted into GCV-triphosphate 
(GCV-TP) by cellular thymidine kinases. GCV-TP incorporated in DNA that led to 
premature termination of DNA and subsequently cell death. GCV (InvivoGen) was 
reconstituted with 20 ml of sterile water, and its pH was adjusted to 12 with NaOH 1M 
because GCV is only soluble at pH ≥ 12. GCV solution’s pH was lowered to 11, and 5 ml 
of sterile water was added to obtain a solution at 10 mg/ml. A 0.22 um sterile filter was 
used to sterilize GCV solution and its aliquots were stored at -20°C.  For in vivo 
treatment, the concentration of the stock solution (10 mg/ml) was diluted to 5 mg/ml by 
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adding the same volume of sterile PBS. The mouse was received daily intraperitoneal 
(i.p.) injections of 2.5 mg of GCV. 
 
Survival study  
For survival study, the time of the death is most critical endpoint. In this study, the 
euthanizing mice with more than 5mm or actively bleeding prolapsed rectum were 
considered as false results and removed from survival study. Daily GCV treatment via 
i.p. injection was initiated at 37 days post tumor induction (n = 24 animals for iKrAP; 
αSMA-TK- group and n = 32 animals for iKrAP; αSMA-TK+ group), and animals 
continued to receive treatment until they became moribund, which was assessed on the 
signs of distress and endpoints including weight loss (> 20%), hunching, prostration, 
impaired motility, and ruffled haircoat. Mice exhibiting limb paresis were evaluated 
again 6 hours later. Then if mice worsened, they were euthanized and considered as non-
survivors.    
 
Histology scoring for local invasion 
The H&E slides from each sample were examined blindly by an investigator and were 
evaluated in the light microscope. The invasion scoring is based upon the measurement of 
the deepest point of primary tumors. The measurement of invasion depth was categorized 
into four scales: 0 (no invasion), 1 (invasion of muscularis mucosa), 2 (invasion of 
submucosa), 3 (invasion of muscularis propria), and 4 (invasion of serosa). 
 
 
	 19	
Immunohistochemistry 
Harvested tumors and lungs were fixed in 10% neutral buffered formalin, dehydrated, 
and embedded in paraffin. For αSMA immunohistochemistry, the deparaffinized tumor 
sections were incubated in 10mM citrate buffer (pH 6.0) for 1 hour at boiling temperature 
before blocking with M.O.M. Mouse IgG Blocking Reagent (Vector Laboratories, West 
Grove, PA) for 1 hour. Sections were incubated with αSMA antibody (1:200, Daco.) 
overnight at 4°C, followed by incubation with biotin-conjugated anti-rabbit/rat/mouse 
IgG and ABC reagent (Vector Laboratories, West Grove, PA) for 30 min each at room 
temperature. The sections were then developed by DAB staining according to the 
manufacturer’s instructions. For collagen 1(1:200, MP bioscience), β-catenin (1:200, 
Abcam), LYVE-1 (1:200, Abcam), we used 4% of fish gel for blocking and followed 
same procedures described above. In the cause of picrosirius red staining, we followed 
manufacturer’s protocol (sigma-Aldrich). 
For Dclk1 and CD20 staining, immunostainings were performed on frozen sections. 
Frozen sections were fixed in acetone for 10 minutes at 4°C and blocked one hour with 
5% donkey or goat serum in PBST at room temperature. Following blocking, sections 
were incubated in 1:200 rat anti- Dclk1 (Abcam) and CK20 (Abcam) at 4°C overnight, 
followed by fluorescent secondary antibodies. Slides were mounted after DAPI staining, 
labeling nuclei blue. 
 
Flowcytometry 
Tumors were excised and cut into 1-2mm2 pieces. Digestion was performed by 
incubating the small pieces at 37°C for one hour in RPMI 1640 medium supplemented 
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with 0.15µg/ml of DNase I(Invitrogen), 40U of Dispase I(Sigma),  and 100U/ml of 
collagenase VIII (Sigma). Following initial one-hour incubation, the pieces were 
vortexed intensively and then incubated at 37°C for 5 min, repeating this step until 
complete digestion. The digestion solution was passed through a 100µm cell strainer and 
washed with RPMI 1640 medium. The cells were resuspended with anti-mouse CD16/32 
and then staining with anti-CD4, CD8, F4/80, CD3e, Gr1, Ly-6C, CD11b, CD19, NK1.1, 
and CD45 conjugated with fluorochromes. 
For Foxp3 staining, Cells were incubated at 37°C for 3 hours with 50ng/ml of PMA 
(Sigma), 500ng/ml of Ionomycin (Sigma) to stimulate cytokine production, and 
Monensin to block protein transport from endoplasmic reticulum to golgi apparatus. 
Fixation and permeabilization working solution (eBioscience) were added and cells were 
incubated at 4°C for 30 min in the dark.  Following the incubation, the cells were stained 
with conjugated anti-mouse Foxp3 antibody and fluorescently conjugated antibodies at 
4°C for 15 min in the dark and resuspended in appropriate volume for flow cytometric 
analysis using LSR II.  
 
Circulating tumor cell (CTC) measurement 
The blood (100ul) was collected retro-orbitally from iKrAP; αSMA-RFP; αSMA-TK- and 
iKrAP; αSMA-RFP; αSMA-TK+ mice and incubated twice with 1ml of ACK lysing 
buffer (A1049201, ThermoFish Scientific) at room temperature to lyse red blood cells. 
ACK-treated cells were washed twice with cold PBS and resuspended in 2% FBS 
containing PBS. The number of GFP+ cells was analyzed by flow cytometry (BD 
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LSRFortessa X-20 Cell Analyzer, BD Biosciences). The data was indicated by the 
percentage of GFP+ cells among 1 × 105 cells. 
 
RNA-Seq 
Tumors were harvested from iKrAP; αSMA-RFP; αSMA-TK- and iKrAP; αSMA-RFP; 
αSMA-TK+ mice. 1ml of TRIzol Reagent (Life Technologies) was added into 50 – 
100mg of samples. Tissues were homogenized by a tissue homogenizer, and 
homogenized sample were incubated for 5 minutes at room temperature. 200ul of 
chloroform per 1ml of TRIzol Reagent were added, and the mixtures were vigorously 
shaken by hand for 15 seconds. The mixtures were centrifuged at 12,000 x g for 15 
minutes at 4 °C. The aqueous phase of the mixtures was collected by pipetting. 0.5ml of 
100% isopropanol was added into the aqueous phase per 1ml of TRIzol Reagent, and 
incubate at room temperature for 10 minutes. The samples were centrifuged at 12,000 x g 
for 10 minutes at 4 °C. To wash pellets, 1ml of 75% ethanol per 1ml of TRIzol Reagent 
was used, and vortex the samples briefly. The samples were centrifuged at 7,500 x g for 5 
minutes at 4 °C. We did air dry RNA pellet for 10 minutes, and added DEPC water. 
The RNA-seq was carried out with three biological replicates. Illumina HiSeq 2000 was 
utilized with 76nt PE sequencing format. A threshold of q value < 0.05 was used. Gene 
set enrichment analyses (GESA) were performed with GSEA platform of the Broad 
Institute. 
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Chapter 3: αSMA+ myofibroblast-ablated tumors exhibit poor survival in 
murine CRC model.  
CRC irresponsive to therapy is a lethal disease. Therefore, innovative treatments that 
eradicate primary tumors and prevent metastatic dissemination to distal organs are 
necessary to improve our capability to cure CRC patients. Tumor microenvironment 
(TME) had long been regarded as a key cellular regulator of the multi-step tumorigenesis 
in CRC. The TME in CRC is quite distinct from the standard tissue microenvironment, 
and it is composed of intra-tumoral bacteria and a particular phenotype of immune cells 
and stromal cells including tumor-associated macrophages (TAMs), tumor-associated 
neutrophils (TANs), and cancer-associated fibroblasts (CAFs). CAFs have been mainly 
known as a potential therapeutic target to tumor progression and metastasis in CRC due 
to their pro-angiogenic and immunosuppressive characteristics in vitro settings. A Recent 
study has revealed that depletion of CAFs constitutes a protective response from the host 
rather than the pro-tumorigenic role in pancreatic ductal adenocarcinoma [94]. Another 
study demonstrated that fibroblast-restricted deletion of IKKβ upregulated intestinal 
epithelial proliferation of intestinal epithelial cells, suppressed apoptosis of cancer cells, 
and promoted the recruitment of CD4+Foxp3+ Tregs [95].  
Based on the previous finding, CAFs have a much wider range of functions. It is not clear 
that functions of different subtypes and signaling pathway involved between CAFs and 
other cells in tumor microenvironment. 
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Mouse model for spontaneous colorectal cancer  
In this study, we utilized a spontaneous mouse model for colorectal cancer (iKrAP) 
containing six alleles: Villin-Cre-ERT2; APCflox/flox; p53flox/flox; tetO-LSL-KrasG12D; 
Rosa26-LSL-Luc; Rosa26-LSL-rtTA-GFP provided by Dr. Adam Boutin in Ronald 
DePinho lab (Figure 1). Unlike other murine CRC models, iKrAP mice reliably 
recapitulate the genetic and histopathological features of human diseases including 
adenoma-carcinoma progression, abundant stroma, and distal metastasis.  
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Figure 1. Spontaneous mouse colorectal cancer mice. Mouse colorectal cancer model 
containing six genetic alleles; VillinCreERT2; tetO-Lox-Stop-Lox-KrasG12D; ROSA26-Lox-Stop-Lox-
rtTA-IRES-EGFP; APCfl/fl; P53fl/fl; ROSA26-Lox-Stop-Lox-Luciferase. Tamoxifen-dependent Cre 
recombinase excision of STOP codon induce deletion of exon 14 in APC gene, deletion of exon 
2-10 in p53 gene, and activation of rtTA. In the presence of doxycycline, rtTA binds tetO and 
initiate transcription of KrasG12D. 
 
αSMA+ myofibroblasts depletion is associated with decreased survival 
To understand the functional significance of αSMA+ myofibroblasts in disease 
progression of colorectal cancer, we crossed iKrAP mice with αSMA-TK and αSMA-
RFP mice that express viral thymidine kinase under control of αSMA promoter (Figure 
2). Viral thymidine kinase phosphorylates Ganciclovir (GCV) to GCV-monophosphate, 
which is further converted to GCV-diphosphate and GCV-triphosphate by host kinases. 
Therefore, the treatment of GCV in αSMA-TK+ mice results in the selective elimination 
of proliferating αSMA+ cells due to incorporation of GCV-triphosphate in DNA as an 
analog of deoxyguanosine by polymerase during replication, leading to termination of 
DNA synthesis and subsequently cell death while αSMA+ cells in αSMA-TK- mice have 
no effect with GCV treatment [96, 97] (Figure 3).  
Tumors were introduced at 8 to10 weeks ages of iKrAP; αSMA-TK- and iKrAP; αSMA-
TK+ mice by intrarectal injection of 4-hydoxy tamoxifen and doxycycline diet. Villin has 
expressed microvilli of the brush border of epithelium in both small and large intestine23. 
Injection of tamoxifen though IP route causes severe damages to both small and large 
intestinal epithelium and all of the mice were moribund within two weeks (Data not 
shown). Therefore, we introduce tamoxifen only via intrarectal anemia. One month later, 
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endoscopy was performed for tumor incidence. Seven days post endoscopy, we daily 
treated GCV via intraperitoneal injection (IP) (Figure 4).  
αSMA+ myofibroblast depletion is associated with significant reduction of survival 
(Figure 5). Around 60% of iKrAP; αSMA-TK+ mice developed hind limb paresis 
whereas all of the iKrAP; αSMA-TK- mice were moribund because of bowel obstruction 
(Figure 6).  
Immunohistochemical analysis of αSMA revealed around 70% reduction of αSMA+ 
myofibroblasts in αSMA-TK+ mice (Figure 7). 
 
 
 
Figure 2. Spontaneous mouse colorectal cancer mice were crossed with αSMA-TK and 
RFP mice to targeting and monitoring, respectively. Mouse colorectal cancer model 
containing six genetic alleles; VillinCreERT2; tetO-Lox-Stop-Lox-KrasG12D; ROSA26-Lox-Stop-Lox-
rtTA-IRES-EGFP; APCfl/fl; P53fl/fl; ROSA26-Lox-Stop-Lox-Luciferase. These mice were bred with 
αSMA-TK and αSMA-RFP mice.  
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Figure 3. Mouse model targeting proliferating αSMA+ myofibroblast by treating GCV. GCV 
is an analog of deoxyguanosine used as a substrate, which is converted into GCV-triphosphate 
(GCV-TP) by cellular thymidine kinases. GCV-TP incorporated in DNA that led to premature 
termination of DNA and subsequently cell death. 
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Figure 4. Experimental timeline for induction of tumors and ablation of αSMA+ 
myofibroblasts. Mice were intrarectally treated with 4-OH tamoxifen (50 mg/kg) and were fed 
with doxycycline pellets (200 mg/kg) at 60 days of age for induction of tumors. 30 days post tumor 
induction, endoscopy was performed to validate tumors in rectal and colon. At 97 days of age, 
GCV were intravenously administrated in tumor-bearing mice. The mice continued to receive 
GCV treatment until they became moribund.  
 
 
 
 
Weight 
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Tumor  
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Days                      60 Days                90 Days       97 Days                   Moribund 
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Tissue  
collection 
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`	
Doxycycline (1.5g/kg, diet) 
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(I.R. 50mg/kg once) 
 
iKrAP; αSMA-TK- 
(Control) 
iKrAP; αSMA-TK+ 
(Depleted) 
10% of animals used for experiments 
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Figure 5. Decreased αSMA+ myofibroblasts correlated with poor survival. Daily GCV 
treatment via i.p. injection was initiated at 37 days post tumor induction. The mice were assessed 
on the sign of distress and endpoints everyday. The median survival of iKrAP; αSMA-TK+ was 28 
days after treatment of GCV whereas that of iKrAP; αSMA-TK- was 41 days. (n=32; iKrAP; 
αSMA-TK+, n=24; iKrAP; αSMA-, ****p<0.001, Mentel-Cox test) 
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Figure 6. Ablation of αSMA+ myofibroblast results in limb paresis whereas non-depleted 
mice were moribund due to bowel obstruction. (A)  (****p<0.0001, T-Test).  (B) Comparison of 
the frequency of paresis (****p<0.0001, Contingency).  
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Figure 7. Decreased aSMA expression in iKrAP; αSMA-TK+ mice. Tumor sections from iKrAP; 
αSMA-TK- and iKrAP; αSMA-TK+ were immunohistochemically stained with αSMA. 
Representative microscopic images and corresponding quantification (n=4; iKrAP; αSMA-TK-, 
n=5; iKrAP; αSMA-TK+, Student T-Test, ****p<0.0001) 
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Chapter 4: αSMA+ myofibroblast-depleted tumors present more invasive 
and metastatic phenotype 
The major cause of death of CRC is the metastasis in liver and lung. The majority of 
patients with metastatic CRC remain incurable, and their median survival is around two 
years. Treatment and investigation of molecular characteristics in CRC only have focused 
on metastatic cancer cells. However, recent studies revealed that development and 
progression of CRC linked to many other aspects consisting ECM, vasculatures, CAFs, 
immune cells. Mainly, CAFs are known as having tumor-promoting characteristics by 
secreting growth factors, cytokines, and chemokines necessary for promoting tumor 
growth and metastasis in vitro setting.   
Our previous finding demonstrated that decreased αSMA+ myofibroblasts correlated with 
poor survival. Therefore, we hypothesized that αSMA+ myofibroblasts-depleted tumors 
display increased metastasis to blood and lymphatic vessels, lung, and liver. 
 
iKrAP; αSMA-TK+ mice exhibited decreased extraluminal tumor burden 
Vertical tumor growth is an independent prognostic parameter for patients with CRC. 
Tumor size [140]. The size was significantly associated tumor progression and cancer-
specific survival in most solid tumors. To investigate comparison of tumor size between 
αSMA+ myofibroblasts-depleted tumors and non-depleted tumors, we harvested tissue 30 
days post GCV treatment and measure tumor size, tumor number, and colon length. 
Interestingly, αSMA+ myofibroblasts-depleted tumors showed that decreased 
extraluminal tumor size whereas tumor numbers was no different between two groups 
(Figure 8A, B). Colon length is one of indicator for colonic inflammation [98]. αSMA+ 
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myofibroblasts-depleted colons were shorter than non-depleted colons, suggesting that 
αSMA+ myofibroblasts-depleted colons sustained more colonic inflammation (Figure 
8C).   
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Figure 8. Depletion of αSMA+ myofibroblasts results in decreased extraluminal tumor 
burden and increased inflammation. (A) (B) Representative colon images from iKrAP; αSMA-
TK- and iKrAP; αSMA-TK+ mice (C) Comparison of tumor size and number, and colon length 
(n=8; iKrAP; αSMA-TK-, n=9; iKrAP; αSMA-TK+, Student T-Test, ns; no significant difference, 
*p<0.05, ****p<0.0001) 
 
αSMA+ myofibroblast-ablated tumors displayed increased frequency of local invasion. 
Next, we measured local invasion score to compare aggressiveness between αSMA+ 
myofibroblast-depleted tumors and non-depleted tumors. CRC arose from epithelium and 
grow vertically, protruding gut lumen. However, aggressive and advanced stages of CRC 
invade muscularis mucosa, submucosa, muscularis propria, and serosa. We measured this 
parameter based on local invasion score (Figure 9E). Non-depleted tumors typically 
exhibited well-differentiated with mostly no local invasion (Figure 9A, B, F). But αSMA+ 
myofibroblasts-depleted tumors displayed poorly differentiated, tumor budding, immune 
cell infiltration in the submucosa, and increased frequency of local invasion (Figure 9C, 
D, F). In conclusion, αSMA+ myofibroblasts-depleted tumors exhibited increased overall 
intraluminal tumor burden. 
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Figure 9. Depletion of αSMA+ myofibroblasts exhibited increased frequency of local 
invasion (A) (B) (C) (D) Representative microscopic images tumors from iKrAP; αSMA-TK- and 
iKrAP; αSMA-TK+ mice and (F) corresponding quantification (Student T-Test, **p<0.001), (E) 
Schematic diagram of scoring system for local invasion. The invasion scoring is based upon the 
measurement of the deepest point of primary tumors. The measurement of invasion depth was 
categorized into four scales: 0 (no invasion), 1 (invasion of muscularis mucosa), 2 (invasion of 
submucosa), 3 (invasion of muscularis propria), and 4 (invasion of serosa). 
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Depletion of αSMA+ myofibroblast in tumor microenvironment affected to develop 
depressed tumors 
Comparison of histopathological observations from previous data between two groups 
indicated that αSMA+ myofibroblasts-depleted tumors were depressed and nonpolypoid 
colorectal cancer which are harder to detect by colonoscopy or computed tomography 
colonography but more aggressive than generic CRC, irrespective of size [99, 100]. To 
further elucidate this finding, we decided to compare tumor sizes at two-time points: 
before and after GCV treatment by endoscopy. Strikingly, αSMA+ myofibroblasts-
depleted tumors mostly exhibited decreased tumor size whereas non-depleted tumors 
display increased tumor size.  
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Figure 10. αSMA+ myofibroblast depletion affected morphological alteration to depressed 
CRC. First endoscopy was performed to both iKrAP; αSMA-TK- (n=6) and iKrAP; αSMA-TK+ 
(n=11)mice before GCV treatment. Once the mice became moribund, the second endoscopy was 
performed. The occupancy of tumors on the gut lumen was calculated with Photoshop.  
Representative colonoscopic images and corresponding quantification  
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Depletion of αSMA+ myofibroblasts increased CTCs 
The major reason of cancer-related mortality is the metastasis of primary tumors to distal 
organs. During efficient dissemination, tumor cells invade the nearby tissues and organs 
of primary tumors, intravasate into blood vessels, migrate distant tissues, extravasate, 
adapt to new microenvironment, and eventually colonize to form metastasis [101].  
The presence of CTCs in cancer patients was first described in 1869 [102] and many 
studies in past decade have shown that CTCs may be used as a biomarker to predict 
disease progression and survival in metastatic tumors. High CTCs numbers were 
relatively correlated with aggressive disease, increased metastasis, and reduced survival.  
To investigate whether depletion of αSMA+ myofibroblasts impacts metastasis, the 
number of GFP+ CTCs from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice was 
counted by FACS. We found that iKrAP; αSMA-TK+ showed dramatically increased 
CTC number (Figure 11).  
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Figure 11. iKrAP; αSMA-TK+ showed increased CTC number. The blood was collected from 
iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice after GCV treatment. GFP+ cells were counted by 
FACS. Representative FACS images and corresponding quantification (Student T-Test, **p<0.01) 
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Depletion of αSMA+ myofibroblasts increased metastasis to lymphatic system 
Lymph node metastasis is the key factor for prognosis of CRC. The 5-year survival of 
patients with lymph node-negative disease is around 70-80% in contrast to 30-60% in 
those with lymph node-positive disease [103].  
To study whether depletion of αSMA+ myofibroblasts impacts metastasis of cancer cells 
to lymph nodes, we first utilized immunohistochemical analysis for lymphovascular 
invasion with lyve-1. αSMA+ myofibroblast depleted tumors exhibited significantly 
increased invasion of cancer cells to lymphatic vessels (Figure 12).  
Next, we further investigated that increased lymphatic vessel invasion correlated with 
local lymph node metastasis. We harvested mesenteric, lumber, and inguinal lymph 
nodes and thymus from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice to measure 
GFP+ cancer cells by FACS. We found that iKrAP; αSMA-TK+ displayed increased 
GFP+ cancer cell number in lymph nodes and thymus (Figure 13).  
 
Depletion of αSMA+ myofibroblasts increased metastasis to pericolonic and perirectal fat 
Pericolonic tumor deposits (PTDs) are metastatic adenocarcinoma nodules occurring in 
the pericolonic and perirectal fat. PTDs are an independent prognostic factor for 
advanced CRCs, and a destructive type of venous invasion different from other types of 
vessel involvement. Many studies showed that the presence of PTDs correlated with 
shorter overall survival in patients with stages III and IV CRCs [143]. Therefore, we 
investigated whether depletion of αSMA+ myofibroblast increased dissemination of 
cancer cells to pericolonic and perirectal fat. Interestingly, depleted animals exhibited the 
remarkable inflammation of pericolonic fat, and histopathological analysis revealed that 
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these inflammation lesions contained adipocytes, immune cells, vasculature, and cancer 
cells (Figure 14A). To confirm histopathological analysis, we performed FACS, and we 
found increased infiltration of cancer cells and immune cell population in depleted 
tumors (Figure 14B).  
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Figure 12. iKrAP; αSMA-TK+ showed increased invasion of cancer cells to lymphatic 
vessels. Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were 
immunohistochemically stained with Β-catenin and LYVE-1 to identify cancer cells and lymphatic 
vessels, respectively. Representative microscopic images and corresponding quantification (n=7; 
iKrAP; αSMA-TK-, n=6; iKrAP; αSMA-TK+, Student T-Test, ***p<0.001) 
 
 
 
 
 
 
Figure 13. iKrAP; αSMA-TK+ showed increased metastasis of cancer cells to the lymphatic 
system. Mesenteric, lumber, and inguinal lymph nodes and thymus were harvested from iKrAP; 
αSMA-TK- and iKrAP; αSMA-TK+ mice after GCV treatment. GFP+ cells were counted by FACS. 
Representative FACS images and corresponding quantification (Student T-Test, *p<0.05) 
 (T-Test, *p<0.05) 
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Figure 14. iKrAP; αSMA-TK+ showed increased metastasis of cancer cells to pericolonic 
and perirectal fat. (A) Pericolonic and perirectal fat were harvested from iKrAP; αSMA-TK- and 
iKrAP; αSMA-TK+ mice after GCV treatment. (B) GFP+ cells were counted by FACS. Single cells 
suspension was stained with anti-CD3, anti-CD45, and anti-CD11b. Representative FACS 
images and corresponding quantification (Student T-Test, *p<0.05) 
 
Depletion of αSMA+ myofibroblasts induce collagen-rich stroma to promote cancer cell 
invasion 
ECM remodeling is tightly regulated during development in normal colon. Abnormal 
ECM production can upregulate integrin signaling and thus can improve cell survival and 
proliferation [104]. Increased collagen contents by LOX overexpression promote ERK 
and PI3 kinase signaling in cancer cells [105]. The properties of ECM also play a 
significant role in regulating both stem cell and cancer stem cells. Abnormal changes of 
ECM disrupt cellular differentiation, resulting in loss of differentiation and increased 
stem cell pool [106].  
A Recent study showed that collagen-1 promotes mesenchymal gene expression and 
stimulate tumor cell invasion and collagen-1 is the most enriched genes in recurrence-
prone tumors in CRC [107].  
Previous our findings revealed that ablation of αSMA+ myofibroblasts induced poorly 
differentiated, more invasive and metastatic tumors. Therefore, it is impossible that 
aberrant expression of collagen contents alters the behavior of cancer cells, aggressive 
phenotype.  
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To test this possibility, picrosirius red staining was performed and revealed that a 
significant increase of collagen contents in αSMA+ myofibroblasts-depleted tumors 
(Figure 15). Additionally, Tumor collagen I assayed by type 1 collagen immunostaining 
was significantly increased αSMA+ myofibroblasts-depleted tumors (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 50	
 
 
 
 
Figure 15. αSMA+ myofibroblasts-depleted tumors revealed increased collagen deposition. 
Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were immunohistochemically 
stained with Sirius Red. Representative microscopic images and corresponding quantification 
(n=4; iKrAP; αSMA-TK-, n=5; iKrAP; αSMA-TK+, Student T-Test, ****p<0.0001) 
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Figure 16. αSMA+ myofibroblasts-depleted tumors displayed increased type I collagen. 
Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were immunohistochemically 
stained with collagen I. Representative microscopic images and corresponding quantification 
(n=4; iKrAP; αSMA-TK-, n=5; iKrAP; αSMA-TK+, Student T-Test, **p<0.01) 
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Chapter 5: Depletion of αSMA+ myofibroblasts results in immune- 
suppressive microenvironment in CRC 
Cancer cells interact with their surroundings for growth, invasion, and metastasis. The 
tumor microenvironment is composed of a diverse range of cells including stroma cells 
and immune cells. The immune system is capable of controlling and shaping tumors 
through a process known as immunoediting; elimination, equilibrium, and escape [108]. 
Experimental evidence has shown that inflammation support tumor development and 
growth [109], but the role of adaptive immune responses is still widely unclear based on 
murine and human studies. Although the presence of high proportion of cytotoxic CD8 T 
cells has been most associated with a better prognosis in CRC, the prognostic assessment 
to infiltration of Foxp3+regulatory T cells (Tregs) has been controversial [110].  
About the prognostic value of Foxp3+Tregs, low CD3+ T cells and Foxp3+ Tregs in stage 
II and stage III CRC is associated with shorter patient survival [111]. Another study 
investigated that the proportion of Foxp3+ Tregs in healthy colon versus tumor tissue and 
found that high Foxp3+ Tregs proportion in tumor tissue was associated with improved 
survival, whereas the high density of Foxp3+ Tregs in the normal colon was associated 
worse prognosis [112].  
Additionally, suppressive immune profiles with increased CD4+Foxp3+ Tregs and 
decreased CD8+ cytotoxic T cells were observed in αSMA+ myofibroblasts-depleted 
mouse pancreatic tumors [94]. 
To interrogate whether depletion of αSMA+ myofibroblasts leads to immunosuppressive 
microenvironment, we performed FACS analysis. We noted that αSMA+ myofibroblasts-
depleted tumors displayed increased percentage of CD4+ Foxp3+ Tregs leading to the 
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overall decrease in Teff/Treg ratio together with reduced percentage of CD8+ cytotoxic T 
cells (Figure 17). 
 
 
 
 
Figure 17. Targeting αSMA+ myofibroblasts exhibited immunosuppressive 
microenvironment. Tumor tissues were harvested and digested with enzyme mixture including 
collagen 8, dispase I, and DNase I. For surface staining, single cell suspension was stained with 
anti CD3e, CD4, CD8, and CD45. For foxp3 staining, cells were fixed with Foxp3 staining kit and 
staining with anti-Foxp3.  (n=6; iKrAP; αSMA-TK-, n=6; iKrAP; αSMA-TK+, Student T-Test, 
**p<0.01, *p<0.05) 
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Chapter 5: Depletion of αSMA+ myofibroblasts results in increase of 
cancer stem cells in CRC 
Many emerging evidence suggests that a small subpopulation of cancer cells, termed 
cancer stem cells (CSCs), are responsible for propagation and dissemination in a very 
efficient manner [113].  Compared normal stem cells, CSCs show slow rate of cell 
cycling responsible for resistance to treatment such as chemotherapy and radiotherapy 
and recurrence [114, 115]. Also, CSCs have a critical feature to initiate new tumors for 
metastatic colonization to the distal organ. 
In CRC, gene expression array to human patient samples revealed that aggressive CRC is 
enriched in intestinal stem cell gene expression including Lgr5 [116]. Also, there was a 
significant increase in Lgr5 expression in patients at stages III and IV comparing to 
stages I and II of CRC. The expression of Dclk1 was also elevated in advanced stages 
[117].  
Since pathological morphology of αSMA+ myofibroblasts-ablated tumor revealed more 
undifferentiated tumors with enhanced invasiveness, we expected increased expression of 
Lgr5 and Dclk1in cancer cells of the αSMA+ myofibroblasts-ablated tumor. 
 
Targeting αSMA+ myofibroblasts increased LGR5+ cancer stem cell population  
To investigate whether αSMA+ myofibroblasts depletion is associated with increased 
Lgr5+ cancer stem cells in CRC, we decided to perform FACS analysis. As we expected, 
tumors with αSMA+ myofibroblasts depletion revealed increased Lgr5 expression on 
cancer cells (Figure 18).  
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Figure 18. Targeting αSMA+ myofibroblasts resulted in the Lgr5+ cell among cancer cells. 
Tumor tissues were harvested and digested with enzyme mixture including collagen 8, dispase I, 
and DNase I. Single cell suspension were stained with anti Lgr5 and CD45. Representative FACS 
images and corresponding quantification (n=5; iKrAP; αSMA-TK-, n=6; iKrAP; αSMA-TK+, 
Student T-Test, *p<0.05) 
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Assessment of Dclk1+ cells in colon cancer cells 
Next, we tested whether depletion of αSMA+ myofibroblasts increases Dclk1+ cancer 
stem cell population. Immunohistochemical analysis revealed that dramatic increased 
Dclk1+ cancer stem cell population when we targeted αSMA+ myofibroblasts (Figure 19).  
 
 
Figure 19. Targeting αSMA+ myofibroblasts led to increased expression of DCLK1 in 
cancer cells. Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were 
immunohistochemically stained with CK20 and DCLK1. Representative microscopic images and 
corresponding quantification (n=4; iKrAP; αSMA-TK-, n=4; iKrAP; αSMA-TK+, Student T-Test, 
**p<0.01) 
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Depletion of αSMA+ myofibroblasts caused to up-regulation of cancer stem cell  
proliferation  
Previous our observation indicated that ablation of αSMA+ myofibroblasts increased the 
frequency of Lgr5+ or Dclk1+ cancer stem cell population in TME. To address molecular 
mechanism regarding this phenotype, we performed RNA sequencing (RNA-seq). We 
found that a significant enrichment of the signature genes in negative regulation of stem 
cell proliferation in control tumors, including pleiotrophin (PTN), singles-type MMTV 
integration site family member 5A (WNT5A), snail homolog 2 (SNAI2), fibulin 1 
(FBLN1), and bone morphogenetic protein 4 (BMP4) (Figure 20). This result highlight 
αSMA+ myofibroblasts play an essential role in regulation of cancer stem cell 
proliferation.  
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Figure 20. Ablation of αSMA+ myofibroblasts resulted in enrichment of negative regulation 
of cancer stem cell proliferation in control tumor. (A) GSEA revealed significant enrichment of 
gene signatures with negative regulation of stem cell proliferation. (B) Comparison of RNA 
rawcount between control tumors and depleted tumors  (n=3; iKrAP; αSMA-TK-, n=3; iKrAP; 
αSMA-TK+, Student T-Test, *p<0.05) 
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Chapter 6: Summary and Discussion 
It is widely believed that CAFs contributes to tumor growth, invasion, and metastasis by 
secreting various growth factors, ECM proteins, chemokines, and cytokines. These 
cellular and extracellular components alter genetic and epigenetic features of cancer cells. 
In this regard, several studies were reported that CAFs correlated with poor prognosis in 
cancer patients. LOXL2 is highly expressed in CAFs, which associated with poor colon 
cancer survival [118]. Expression of PDGF receptor on CAFs is associated with 
metastasis and poor survival in CRC [119]. Our data demonstrate that ablation of αSMA+ 
myofibroblasts results in multiple effects likely leading to reduced survival. These results 
indicated that αSMA+ myofibroblasts have a protective role in CRC.  
Several studies have been proposed that myofibroblasts can be a putative target for 
cancer therapy because of their pro-invasive activity in vitro culture and tumor xenograft 
mouse model. Only when adding conditioned media from myofibroblast culture isolated 
from surgical colon cancer fragments, colon cancer cells invaded collagen gel [141]. 
Coimplantation of colon cancer cells and myofibroblasts dramatically increased 
invasiveness of colon cancer cells [80], [120]. We demonstrated that αSMA+ 
myofibroblasts-ablated tumors exhibited increased local invasion, lymphovascular 
invasion, CTCs number, and lymph node metastasis. Additionally, the morphology of 
αSMA+ myofibroblasts-ablated tumors was similar with non-polypoid tumors that are 
relatively depressed and flat but have a high risk of local invasion regardless of size. 
Therefore, we speculated that αSMA+ myofibroblasts served as the physical barrier to 
prevent migration of cancer cells to blood and lymphatic vasculatures.  
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One of our interesting findings is that depletion of αSMA+ myofibroblasts results in 
remodeling of the ECM with increased collagen contents in TME. Many studies 
suggested that αSMA+ myofibroblasts and type I collagen are associated with tumor 
progression [121-123]. It is widely accepted that myofibroblasts mainly contribute to the 
production of type I collagen in TME but recent studies demonstrated that cancer cells 
and other stroma cells secrete Type I collagen [124] [142]. Also, fibroblasts such as 
FAP+ , FSP1+, or vimentin+ subpopulation could compensate collagen deposits.  
Myofibroblasts are also the primary source of ECM-degrading proteins including MMPs. 
In these respects, we can postulate that cancer cells and other stroma cells may 
compensate production of type I collagen or lack of MMP2 and MMP7 secreted by 
αSMA+ myofibroblasts. This causes a reduction in the efficacy of degradation of collagen 
contents in TME. 
Another impact of αSMA+ myofibroblast depletion was the alteration of immune cell 
infiltration. Although most of the studies elucidating tumor-promoting functions of CAFs 
were driven by co-culture experiments, CAFs are considered as a facilitator of 
immunosuppressive TME. CAFs stimulated IL-6 signaling pathway on dendritic cells to 
inhibit maturation, resulting in T cell anergy [125].  CAFs isolated human non-small cell 
lung cancer expressed PD-L1 and PD-L2 [126]. In vivo study, depletion of αSMA+ 
myofibroblasts led to immunosuppressive adaptive immunity with increased Foxp3+ Treg 
infiltration in PDAC [94]. We demonstrated that T cell-mediated immune responses were 
impaired when αSMA+ myofibroblasts were ablated. αSMA+ myofibroblast-depleted 
tumors exhibited increased Foxp3+ Treg infiltration along with decreased recruitment of 
CD8+ cytotoxic T cells. Also, tumor-expressing collagens can trigger an inhibitory 
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signaling via leukocyte-associated Ig-like receptors (LAIRs) for inactivation of cytotoxic 
NK cells [127]. This study supported that aberrant deposition of collagen contents 
promoted immunosuppressive TME in αSMA+ myofibroblast-depleted tumors.  
The most striking effect when αSMA+ myofibroblasts were depleted is increased 
stemness in cancer cells. CAFs are considered as a putative regulator of cancer stem cells 
because of major capability to secrete ECM proteins that interact ECM receptors to 
acquire or maintain stem cell properties. CAFs may induce epithelial-mesenchymal 
transition (EMT)-driven cancer stemness in prostate cancer via reciprocal interaction 
between cancer cells and CAFs [128]. IGF1R signaling in cancer cells was activated in 
the presence of CAFs that induce Nanog expression and promote stemness in non-small 
cell lung cancer [129]. Our data showed that the proportion of cancer stem cell 
population expressing Lgr5+ or Dclk1+ was increased in αSMA+ myofibroblast-depleted 
tumors. RNA-seq data revealed that gene signatures associated with down-regulation of 
stem cell proliferation were enriched in non-depleted tumors. Therefore, it is possible that 
aberrant collagen deposition in αSMA+ myofibroblast-depleted tumors led to stem cell 
overexpression and loss of differentiation.  
In summary, our data demonstrated a protective role of αSMA+ myofibroblasts in CRC 
and targeting αSMA+ myofibroblasts resulted in diminished survival with the aggressive 
tumor, aberrant collagen deposit, accumulation of Foxp3+ Tregs, and increased cancer 
stem cell population (Figure 21). 
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Figure 21. Summary. Our study reveals unknown functional role of myofibroblasts in 
regulating T cell-meditated anti-tumor immunity and stemness features in colon cancer 
cells 
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